Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ATIC | P31939 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789131 | 0.86 | SMN1; SMN2 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL28006571 | 0.82 | HSD17B10 (0.67) | HPGDCYP2C9TSHRALOX12HSD17B10 | |
| SCHEMBL5085746 | 0.81 | HNF4A (0.63) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL496484 | 0.81 | KDM4E (0.62) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL8202718 | 0.78 | PRKAB2 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL9618861 | 0.77 | HSD17B10 (0.74) | GPR35HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL6206680 | 0.75 | GPR35 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL27722168 | 0.75 | HPGD (0.54) | GPR35HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL2789467 | 0.75 | MCL1 (0.50) | HPGDCYP2C9TSHRALOX12HSD17B10 | |
| SCHEMBL2790332 | 0.75 | HSD17B10 (0.57) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-1888513-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006125778-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-1888513-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006125778-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | SERPINE1 4442/4885PRKAB2 1478/4885PRKAG1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.